C 21 H 26 N 2 O5, monoclinic, P21/c (no. 14), a = 19.779(9) Å, b = 5.332(2) Å, c = 18.945(8) Å, β = 94.572(6)°, V = 1991.4(15) Å 3 , Z = 4, Rgt(F) = 0.0425, wR ref (F 2 ) = 0.1179, T = 298(2) K.
Source of material
The title molecule was synthesized by refluxing 1,3-diamino-2-propanol (0.09 mL, 1 mmol) and 3-ethoxy salicylaldehyde (0.332 g, 2 mmol). The yield is ca. 32% 
Experimental details
The C-bound H atoms were geometrically placed (C-H = 0.95-0.98 Å) and refined as riding with U iso (H) = 1.2-1.5 Ueq(C). The O-and N-bound H atoms were located in a difference Fourier map but were refined with a distance restraint of N-H = 0.88 ± 0.01 Å, and with U iso (H) set to 1.2 Ueq(N) [3] .
Comment
There are several complexes containing the deprotonated title molecule as an anionic ligand, which have been reported, however, the structure about this ligand has not been reported [4] [5] [6] . The compound crystallizes in the monoclinic space group P21/c with four formula units in the unit cell. As shown in the figure, each molecule formally consists of two 3-ethoxysalicylidenyl and one 2-hydroxyl-1,3-propanediamine-diyl moieties. It is observed that the phenolic proton is transferred to the imine nitrogen in the structure of this molecule to yield a ylidic structure. The NH group and phenolate O atom form a strong intramolecular N-H· · · O hydrogen bond. The N-H· · · O hydrogen-bonded rings are almost planar and coupled with the cyclohexadiene rings [7, 8] .
